# Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients

> **NCT07715929** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Yunlong Wang** · enrollment: 710 (estimated)

## Conditions studied

- Atrial Fibrillation
- Obesity & Overweight
- Catheter Ablation

## Interventions

- **DRUG:** Tirzepatide
- **BEHAVIORAL:** Structured Lifestyle Intervention

## Key facts

- **NCT ID:** NCT07715929
- **Lead sponsor:** Yunlong Wang
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2029-09-01
- **Final completion:** 2029-12-30
- **Target enrollment:** 710 (ESTIMATED)
- **Last updated:** 2026-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07715929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07715929, "Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07715929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*